Docetaxel generic
docetaxel is an anti-cancer drug owned by Shilpa. Its active ingredient, also named docetaxel, is primarily used in the treatment of various types of advanced or metastatic cancer. The drug was first authorized for market use on 22nd December 2015 and comes in injectable dosage forms. Shilpa currently holds four patents for docetaxel.
When will Docetaxel generic be available?
The generic version of Docetaxel could be available after 30th September 2033, following the expiration of its last major patent. One notable patent includes a non-aqueous taxane formulation method with the patent number US9763880, which expires on 2033-09-30.
Docetaxel uses
docetaxel is primarily used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy, squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil, operable node-positive breast cancer in combination with doxorubicin and cyclophosphamide, breast cancer after failure of prior chemotherapy and androgen independent metastatic prostate cancer in combination with prednisone. It is also useful in the treatment of advanced gastric adenocarcinoma in combination with cisplatin and fluorouracil. Certain methods of administering docetaxel to a subject involve combining the docetaxel pro-emulsion formulation with an aqueous medium to produce a docetaxel emulsion.
Docetaxel patent expiration
Docetaxel is protected by four patents, with none expired yet. The last patent, identified as US9763880 for non-aqueous taxane formulations and methods of using the same, is set to expire on 30th September 2033. This expiration date impacts the release date of a Docetaxel generic. Below are the details of the patent: